These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19246730)

  • 21. Applying physiological and biochemical concepts to optimize biological drug development.
    Lowe PJ
    Clin Pharmacol Ther; 2010 Apr; 87(4):492-6. PubMed ID: 20147897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal crossover designs in the presence of carryover effects.
    Laska E; Meisner M; Kushner HB
    Biometrics; 1983 Dec; 39(4):1087-91. PubMed ID: 6671121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs.
    Santen G; Horrigan J; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2009 Sep; 86(3):255-62. PubMed ID: 19675543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethically attractive dose-finding designs for drugs with a narrow therapeutic index.
    Lledó-García R; Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2012 Jan; 52(1):29-38. PubMed ID: 21228403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
    Bertino JS; Greenberg HE; Reed MD;
    J Clin Pharmacol; 2007 Apr; 47(4):418-22. PubMed ID: 17389550
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of drugs in pediatrics using K-PD models: perspectives.
    Tod M
    Fundam Clin Pharmacol; 2008 Dec; 22(6):589-94. PubMed ID: 19049659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying and validating novel targets with in vivo disease models: guidelines for study design.
    Anders HJ; Vielhauer V
    Drug Discov Today; 2007 Jun; 12(11-12):446-51. PubMed ID: 17532528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal designs for clinical trials with second-order polynomial treatment effects.
    Winkens B; Schouten HJ; van Breukelen GJ; Berger MP
    Stat Methods Med Res; 2007 Dec; 16(6):523-37. PubMed ID: 17698939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs.
    Santen G; van Zwet E; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2009 Sep; 86(3):248-54. PubMed ID: 19657333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactive computer program for optimal designs of longitudinal cohort studies.
    Tekle FB; Tan FE; Berger MP
    Comput Methods Programs Biomed; 2009 May; 94(2):168-76. PubMed ID: 19131139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials.
    Jones AP; Riley RD; Williamson PR; Whitehead A
    Clin Trials; 2009 Feb; 6(1):16-27. PubMed ID: 19254930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal sampling theory: An overview of its application to pharmacokinetic studies in infants and children.
    Reed MD
    Pediatrics; 1999 Sep; 104(3 Pt 2):627-32. PubMed ID: 10469805
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical pharmacology in the molecular era.
    Dollery CT
    Clin Pharmacol Ther; 2008 Feb; 83(2):220-5. PubMed ID: 18202688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sampling schedule design towards optimal drug monitoring for individualizing therapy.
    Ji S; Zeng Y; Wu P; Lee EJ
    Comput Methods Programs Biomed; 2005 Oct; 80(1):57-63. PubMed ID: 16040154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Models for disease progression: new approaches and uses.
    Mould DR
    Clin Pharmacol Ther; 2012 Jul; 92(1):125-31. PubMed ID: 22617225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in analgesic drug development.
    Hewitt DJ; Hargreaves RJ; Curtis SP; Michelson D
    Clin Pharmacol Ther; 2009 Oct; 86(4):447-50. PubMed ID: 19675542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.